toluene-4-sulfonic acid 2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)ethyl ester | 328919-26-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: toluene-4-sulfonic acid 2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)ethyl ester
• 英文别名: 2-[5-methyl-2-(3-phenylphenyl)-1,3-oxazol-4-yl]ethyl 4-methylbenzenesulfonate
• CAS: 328919-26-2
• 化学式: C₂₅H₂₃NO₄S
• 分子量: 433.528
• InChiKey: CVCAMPCJPLHLFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  77.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  toluene-4-sulfonic acid 2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)ethyl ester 在 sodium hydroxide 、 caesium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)ethoxy]-phenyl}-2-methyl-2-phenoxypropionic acid
  参考文献：
  名称：

  Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis

  摘要：

  To understand the species selectivity in a series of a-methyl-a-phenoxy carboxylic acid PPARalpha/gamma dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARalpha. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARalpha leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARalpha agonist to a human and mouse dual agonist within the same platform.(C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.031
• 作为产物：
  描述：

  [2-(3-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 在 吡啶 、 4-二甲氨基吡啶 、 palladium diacetate 、 氢氧化钾 、 硼烷 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇甲醚 为溶剂， 生成 toluene-4-sulfonic acid 2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)ethyl ester
  参考文献：
  名称：

  Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis

  摘要：

  To understand the species selectivity in a series of a-methyl-a-phenoxy carboxylic acid PPARalpha/gamma dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARalpha. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARalpha leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARalpha agonist to a human and mouse dual agonist within the same platform.(C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.031

文献信息

• Modulators of peroxisome proliferator activated receptors
  申请人：Eli Lilly & Company

  公开号：US06417212B1

  公开（公告）日：2002-07-09

  The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R6 is H, a C1-C4 alkyl, or an aminoalkyl.

  本发明涉及由结构式I表示的化合物及其药学上可接受的盐、溶剂和水合物，以及制备方法、使用方法和具有由结构式I表示的化合物及其药学上可接受的盐、溶剂和水合物的药物组合物：在结构式I中，n为2、3或4；V为O或S；W为O、S或SO2；R1为H、C1-C4烷基、苯基或三氟甲基；R2分别为H、C1-C6烷基、芳基-C1-C6烷基、环烷基-C1-C4烷基、芳基、环烷基，或者与它们结合的苯基一起形成萘基或1,2,3,4-四氢萘基；R3分别为H、C1-C6烷基、芳基-C1-C6烷基、环烷基-C1-C4烷基、芳基或环烷基；R4分别为H、C1-C4烷基、芳基或苄基；R5分别为H、取代或未取代的芳基或杂环烷基，但至少有一个R5是取代或未取代的芳基或取代或未取代的杂环烷基；R6为H、C1-C4烷基或氨基烷基。
• [EN] HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR<br/>[FR] COMPOSES HETEROCYCLIQUES UTILISES COMME MODULATEURS DES RECEPTEURS ACTIVES PROLIFERATEURS DU PEROXYSOME (PPAR), UTILES DANS LE TRAITEMENT ET/OU LA PREVENTION DE TROUBLES MODULES PAR UN PPAR
  申请人：LILLY CO ELI

  公开号：WO2005051945A1

  公开（公告）日：2005-06-09

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式(I)的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。
• Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
  申请人：——

  公开号：US20040138277A1

  公开（公告）日：2004-07-15

  1 Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

  对PPAR受体进行调节的新型化合物，以及其药用盐、溶剂合物和水合物，制备这些化合物的过程，含有这些化合物或其药用盐、溶剂合物和水合物的药物组合物。
• Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids:  A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists
  作者：Yanping Xu、Christopher J. Rito、Garret J. Etgen、Robert J. Ardecky、James S. Bean、William R. Bensch、Jacob R. Bosley、Carol L. Broderick、Dawn A. Brooks、Samuel J. Dominianni、Patric J. Hahn、Sha Liu、Dale E. Mais、Chahrzad Montrose-Rafizadeh、Kathy M. Ogilvie、Brian A. Oldham、Mary Peters、Deepa K. Rungta、Anthony J. Shuker、Gregory A. Stephenson、Allie E. Tripp、Sarah B. Wilson、Leonard L. Winneroski、Richard Zink、Raymond F. Kauffman、James R. McCarthy

  DOI：10.1021/jm0342616

  日期：2004.5.1

  The design and synthesis of the dual peroxisome proliferator activated receptor (PPAR) alpha/gamma agonist (S)-2-methyl-3-[4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)ethoxy]phenyl]-2-pheno xypropionic acid (2) for the treatment of type 2 diabetes and associated dyslipidemia are described. 2 possesses a potent dual hPPAR alpha/gamma agonist profile (IC(50) = 28 and 10 nM; EC(50) = 9 and 4 nM, respectively

  双过氧化物酶体增殖物激活受体（PPAR）α/γ激动剂（S）-2-甲基-3- [4- [2-（5-甲基-2-噻吩-2-基-恶唑-4）的设计与合成描述了用于治疗2型糖尿病和相关血脂异常的（-基）乙氧基]苯基] -2-苯氧基丙酸（2）。2具有有效的双重hPPARα/γ激动剂特性（对于hPPARalpha和hPPARgamma，IC（50）= 28和10 nM； EC（50）= 9和4 nM）。在临床前模型中，2可显着改善胰岛素敏感性，并有效逆转糖尿病性高血糖症，同时显着改善总体脂质体内平衡。
• [EN] BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS<br/>[FR] DERIVES DE BIARYL-OXA(THIA)ZOLE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PPAR
  申请人：LILLY CO ELI

  公开号：WO2001016120A1

  公开（公告）日：2001-03-08

  Compounds represented by Formula (I) wherein n is 2, 3, or 4; V is O or S; W is O, S, or SO2 and at least one R5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; are modulators of peroxisome proliferator activated receptors and are useful in the treatment of type II diabetes and of cardiovascular diseases.

  公式（I）所代表的化合物中，其中n为2、3或4；V为O或S；W为O、S或SO2，且至少有一个R5为取代或未取代的芳基或取代或未取代的杂环基；是过氧化物酶体增殖物激活受体的调节剂，并且在治疗2型糖尿病和心血管疾病方面有用。